Drug Treatment of Heart Failure with Reduced Ejection Fraction: Defining the Role of Vericiguat Andrew J. S. CoatsHeli Tolppanen Current Opinion 03 September 2021 Pages: 1599 - 1604
Bruton’s Tyrosine Kinase Inhibition as an Emerging Therapy in Systemic Autoimmune Disease Stefan F. H. NeysJasper RipOdilia B. J. Corneth Leading Article Open access 05 October 2021 Pages: 1605 - 1626
Pharmacological Management of Acute Endodontic Pain Asma A. KhanAnibal Diogenes Review Article 07 October 2021 Pages: 1627 - 1643
Bone Mineral Density Loss and Fracture Risk After Discontinuation of Anti-osteoporotic Drug Treatment: A Narrative Review Laura P. B. ElbersHennie G. RatermanWillem F. Lems Review Article Open access 15 September 2021 Pages: 1645 - 1655
Tralokinumab: First Approval Sean Duggan AdisInsight Report Open access 18 August 2021 Pages: 1657 - 1663
Belumosudil: First Approval Hannah A. Blair AdisInsight Report Open access 31 August 2021 Pages: 1677 - 1682
Imeglimin Hydrochloride: First Approval Yvette N. Lamb AdisInsight Report 01 September 2021 Pages: 1683 - 1690
Comment on: “MicroRNA Mimics or Inhibitors as Antiviral Therapeutic Approaches Against COVID-19” Song ZhangFeng Zhu Letter to the Editor 28 August 2021 Pages: 1691 - 1692
Reply to Zhang and Zhu “MicroRNA Mimics or Inhibitors as Antiviral Therapeutic Approaches Against COVID-19” Nadine AhmedJohn Paul Pezacki Letter to the Editor 28 August 2021 Pages: 1693 - 1695
Correction to: Vedolizumab and Extraintestinal Manifestations in Inflammatory Bowel Disease Jurij HanzelChristopher MaBrian G. Feagan Correction 28 August 2021 Pages: 1697 - 1697
Correction to: Budesonide/Glycopyrronium/Formoterol: A Review in COPD Young-A Heo Correction Open access 28 August 2021 Pages: 1699 - 1699
Correction to: Aducanumab: First Approval Sohita Dhillon Correction 15 September 2021 Pages: 1701 - 1701
